VANCOUVER, B.C. – SOLVE FSHD, the venture-philanthropy organization founded by entrepreneur Chip Wilson, announces its financial support to the FSHD Canada Foundation’s strategic investment of US$1.2M in biomarker grant funding to facilitate biomarker research in facioscapulohumeral muscular dystrophy (FSHD). The FSHD Canada Foundation acknowledges the generous support of SOLVE FSHD towards funding these grants.
The biomarker grants have been awarded to the following projects: Circulating biomarkers of disease activity in FSHD: Skeletal muscle exosomes (Professor Enzo Ricci and Dr. Giorgio Tasca, Catholic
University of the Sacred Heart, Rome, Italy); IMPROVE FSHD: Artificial intelligence analysis to validate new serum biomarkers and therapeutic target for FSHD and UNDERSTAND FSHD2: An 18-month
prospective natural history study to gain insight FSHD2 pathophysiology and disease progression (Dr. Sabrina Sacconi, Nice University Hospital Center); and Investigation of circulating biomarkers
in FSHD (Dr. Yi-Wen Chen, Children’s National Hospital, Washington, DC).